Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial

Preliminary data suggest promising activity of loncastuximab tesirine in follicular lymphoma, and synergistic activity between rituximab-induced cytotoxicity and loncastuximab tesirine. In this study, we evaluated loncastuximab tesirine combined with rituximab for second-line and later treatment of...

Full description

Saved in:

Bibliographic Details
Published in:	The Lancet. Haematology Vol. 12; no. 1; p. e23
Main Authors:	Alderuccio, Juan Pablo, Alencar, Alvaro J, Schatz, Jonathan H, Kuker, Russ A, Pongas, Georgios, Reis, Isildinha M, Lekakis, Lazaros J, Spiegel, Jay Y, Sandoval-Sus, Jose, Beitinjaneh, Amer, Stanchina, Michele D, Trabolsi, Asaad, Lossos, Izidore S, Rosenblatt, Joseph D, Lessen, David S, Moskowitz, Craig H
Format:	Journal Article
Language:	English
Published:	England 01.01.2025
Subjects:	Adult Aged Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Benzodiazepines Female Humans Immunoconjugates - adverse effects Immunoconjugates - therapeutic use Lymphoma, Follicular - drug therapy Male Middle Aged Neoplasm Recurrence, Local - drug therapy Rituximab - administration & dosage Rituximab - adverse effects Rituximab - therapeutic use
ISSN:	2352-3026, 2352-3026
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!